Agrawal, Saaket http://orcid.org/0000-0002-2535-4759
Klarqvist, Marcus D. R. http://orcid.org/0000-0001-7630-2708
Diamant, Nathaniel http://orcid.org/0000-0002-1738-304X
Stanley, Takara L.
Ellinor, Patrick T.
Mehta, Nehal N.
Philippakis, Anthony http://orcid.org/0000-0001-6953-3794
Ng, Kenney
Claussnitzer, Melina
Grinspoon, Steven K.
Batra, Puneet http://orcid.org/0000-0001-6822-0593
Khera, Amit V.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (1K08HG010155)
Article History
Received: 30 July 2022
Accepted: 20 December 2022
First Online: 17 January 2023
Competing interests
: S.A. has served as scientific consultant for Third Rock Ventures. M.D.R.K., N.D., A.P., and P.B. are supported by grants from Bayer AG applying machine learning in cardiovascular disease. T.L.S. has served on an advisory board for Theratechnologies and RosVivo Therapeutics and has received grant funding to her institution from Pfizer, Inc. P.T.E. receives sponsored research support from Bayer AG and IBM and has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics. A.P. is also employed as a Venture Partner at GV and consulted for Novartis; and has received funding from Intel, Verily and MSFT. K.N. is an employee of IBM Research. P.B. serves as a consultant for Novartis. S.K.G has consulted for and received research funds from Theratechnologies and Viiv through his institution. He has received research funds from KOWA and Gilead unrelated to this project also through his institution. A.V.K. is an employee and holds equity in Verve Therapeutics; has served as a scientific advisor to Amgen, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; and received a sponsored research agreement from IBM Research. The remaining authors declare no competing interests.